深圳微芯生物科技股份有限公司 章程 二〇二五年十一月 | | | 深圳微芯生物科技股份有限公司 章程 | 则 . | | --- | | 营宗旨和范围 | | り . | | 股份发行 . | | 股份增减和回购 . | | 股份转让 . | | 东和股东会 . | | 股东的一般规定 . | | 控股股东和实际控制人 . | | 股东会的一般规定 . | | 股东会的召集 … | | 股东会的提案与通知 | | 股东会的召开 . | | 股东会的表决和决议 | | 事和董事会 | | 董事的一般规定 | | 董事公 … | | 独立董事 | | 董事会专门委员会 … | 第一章 总则 | 7 生于FF (以/)/人 | | --- | | 第二节 董事会 | | 第三节 独立董事 . | | 第四节 董事会专门委员会 | | 第六章 高级管理人员 | | 第七章 财务会计制度、利润分配和审计 | | 第一节 财务会计制度 . | | 第二节 内部审计 . | | 第三节 会计师事务所的聘任 | | 第八章 通知和公告 . | | 第一节 通知 . | | 第二节 公告 | | 第九章 合并、分立、增资、减资 ...

微芯生物公告，公司股东博奥生物及其一致行动人天府清源控股有限公司于2025年10月23日至2025年11 月19日期间，通过竞价交易和大宗交易方式合计减持公司股份482.95万股。博奥生物及其一致行动人合 计持有公司股份比例从10.00%减少至8.82%，权益变动触及1%刻度。本次权益变动为履行此前披露的减 持股份计划，不涉及资金来源，减持计划尚未实施完毕，信息披露义务人仍处于减持期。 ...

Core Insights - On November 19, Microchip Biotech executed a block trade of 811,000 shares, amounting to 20.3642 million yuan, which accounted for 8.23% of the total trading volume for the day [1] - The transaction price was 25.11 yuan, representing a 10% discount compared to the market closing price of 27.9 yuan [1] Summary by Category Trading Activity - The block trade involved a total of 811,000 shares at a price of 25.11 yuan per share [1] - The total transaction value reached 20.3642 million yuan [1] Market Impact - The executed trade price was 10% lower than the market closing price, indicating a significant discount [1] Institutional Participation - The trade was primarily conducted by institutional investors, with various buying and selling departments involved [2]

Group 1 - The report emphasizes the rapid development of China's innovative pharmaceuticals, highlighting that the number of clinical trials has reached a global leading position, with a significant increase in new drug approvals [3][5][7] - Chinese pharmaceutical companies are transitioning from a "fast follower" to an "innovation leader" model, actively engaging in cutting-edge fields such as ADC, bispecific antibodies, and mRNA vaccines, with a notable increase in the number of products in late-stage development [8][11][18] - The report identifies two main investment directions: the transformation of biotech companies into biopharma and the revaluation of traditional pharmaceutical companies during their innovation transition, suggesting specific companies to watch in both categories [3][4] Group 2 - China's integration into the global innovative drug value chain is deepening, with a growing number of global multi-center clinical trials led by Chinese companies, indicating a shift in the global drug development landscape [3][24] - The report notes that the contribution of Chinese companies to global clinical trials has significantly increased, with a projection of 1,903 innovative drug clinical trials registered in China by 2024 [7][24] - The report highlights the increasing competitiveness of Chinese companies in high-potential therapeutic areas, particularly in oncology, metabolic diseases, and autoimmune diseases, with substantial market shares in these segments [18][19] Group 3 - The report discusses the rising trend of BD (business development) transactions involving Chinese assets, with a notable increase in transaction amounts and numbers, indicating China's growing influence in the global pharmaceutical innovation landscape [33][44] - It highlights that the majority of license-out projects are now in early stages, reflecting the international interest in early-stage Chinese innovations, particularly in oncology and metabolic therapies [39][44] - The report points out that major multinational corporations (MNCs) are increasingly seeking next-generation blockbuster products from China to fill revenue gaps due to impending patent expirations [62][66]

Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the development paths of innovative drugs and the role of AI in drug research and development [1][2] - Industry experts emphasized the need for Chinese pharmaceutical companies to shift from "follower" to "leader" by addressing unmet medical needs and leveraging innovative technologies [1][2] Group 1: Conference Highlights - The conference theme was "Bay Area Innovation, Navigating New Journeys," discussing key topics such as dual circulation development, accelerated technology transfer, and compliance in global expansion [1] - Notable speakers included industry leaders and experts, highlighting the importance of innovation and internationalization as core drivers for Chinese pharmaceutical companies [2] Group 2: Regulatory and Industry Perspectives - The Director of the Guangdong Provincial Drug Administration stressed the importance of drug quality and safety, urging companies to strengthen regulatory compliance and communication with authorities to avoid approval delays [1] - The conference aimed to inject new vitality into the biopharmaceutical industry in the Greater Bay Area and across China, promoting high-quality development and attracting talent and projects [1]

Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the theme "Bay Area Innovation, Navigating New Journeys" [1] - Key topics discussed included the dual circulation development path for innovative drugs, acceleration of technology transfer, compliant global expansion, and the role of AI in empowering the entire drug development chain [1] Group 1 - The conference was co-hosted by the Guangdong Provincial Biopharmaceutical Innovation Technology Association and the Guangzhou Science and Technology Progress Foundation, with participation from various organizations including Boji Pharmaceutical Technology Co., Ltd. [1] - The event aimed to explore solutions for innovative drugs in the current complex environment, injecting new vitality and wisdom into the innovation development of the biopharmaceutical industry in the Greater Bay Area and nationwide [1] Group 2 - Notable attendees included prominent figures such as academician Zhong Nanshan, various directors from health authorities in Guangdong, Hong Kong, and Macau, and leaders from over 1,000 top scientists and industry leaders [2] - The conference provided a platform for discussing the future development and innovative practices in the biopharmaceutical sector within the Greater Bay Area [2]

Summary of Key Points Core Viewpoint - Microchip Biotech experienced significant trading activity on November 13, with a total of 9 transactions on the block trading platform, amounting to 1.181 million shares and a total transaction value of 30.7533 million yuan, indicating a discount of 13.63% compared to the closing price of the day [2]. Trading Activity - The average transaction price was 26.04 yuan, which is 13.63% lower than the closing price of 30.15 yuan on the same day [2]. - Institutional trading desks participated in 4 of the transactions, with a total transaction value of 13.1242 million yuan, resulting in a net purchase of 13.1242 million yuan [2]. - Over the past three months, Microchip Biotech has recorded a total of 10 block trades, with a cumulative transaction value of 34.4253 million yuan [2]. Stock Performance - The closing price of Microchip Biotech on November 13 was 30.15 yuan, reflecting a 3.04% increase, with a daily turnover rate of 3.21% and a total trading volume of 392 million yuan [2]. - The stock has seen a net outflow of 23.5728 million yuan in main capital for the day, and a cumulative decline of 1.12% over the past five days, with a total net outflow of 50.6034 million yuan [2]. Margin Trading Data - The latest margin financing balance for Microchip Biotech is 664 million yuan, which has decreased by 11.8255 million yuan over the past five days, representing a decline of 1.75% [2].

| 交易日期 | 证券简称 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-13 | 微芯生物 | 688321 | 26.04 | 260.4 | 10 | 有限公司北京望祭 | 公司深圳章受准秀 | | 2025-11-13 | 微芯生物 | 688321 | 26.04 | 208.32 | 8 | 机构专用 | 公司深圳堂安海秀 | | 2025-11-13 | 微芯生物 | 688321 | 26.04 | 200.51 | 7.7 | 华泰证券股公营限 | 公司深圳景安温秀 | | 2025-11-13 | 微芯生物 | 688321 | 26.04 | 200.51 | 7.7 | 机构专用 | 公司深圳青年温泉 | | 交易日期 | 证券简称 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 英出营业部 | | --- | --- | --- | --- | --- | -- ...

Core Insights - The "Jin Jie You Cu" event in Chengdu facilitates direct communication between enterprises and government departments, addressing challenges faced by the biopharmaceutical industry [1][6] - Chengdu's biopharmaceutical industry is experiencing rapid growth, with a market size exceeding 400 billion yuan and a strong focus on innovation and collaboration [7][8] Group 1: Event Overview - The "Jin Jie You Cu" event gathered over 30 enterprises, government officials, and industry experts to discuss challenges and solutions in the biopharmaceutical sector [1] - Companies like Kelun Pharmaceutical and Microchip Biotech highlighted the importance of direct dialogue with government representatives to resolve issues [1][6] Group 2: Company Challenges - Chengdu-based companies face difficulties in hospital admissions for their innovative products, with a call for policies to prioritize local medical devices [3][6] - Microchip Biotech emphasized the need for better access to clinical resources and support for innovative drug development [3][6] Group 3: Government Responses - Government departments responded to company concerns by outlining support for new drug research and addressing regulatory challenges [6] - The Chengdu Municipal Science and Technology Bureau is focusing on supporting projects that align with enterprise needs, particularly in high-end medical equipment [6] Group 4: Industry Development - Chengdu's biopharmaceutical industry is positioned for significant growth, with a focus on research and development, market expansion, and integration of medical and engineering sectors [7][8] - Recent policies aim to enhance the ecosystem for biopharmaceuticals, including financial incentives for innovative drug development [8][9]

Core Viewpoint - Microchip Biotech (688321) has experienced a slight decline in stock price, closing at 30.41 yuan, down 1.49% from the previous week, with a current market capitalization of 12.401 billion yuan [1] Group 1: Clinical Research Updates - The Phase II clinical trial of Xioroni for pancreatic cancer has enrolled 42 patients, with a 6-month progression-free survival (PFS) rate of nearly 80%, showing better efficacy compared to historical chemotherapy results [3][9] - The sales of Sigleth sodium increased by 125.7% in the first half of 2025, with a year-on-year growth rate of 136.1% in the first three quarters, attributed to successful self-operated and commissioned sales models [4][9] - The Phase III clinical trial of Sidabamine for colorectal cancer has enrolled over 300 patients, leading the domestic competition in similar indications, with expectations to complete most patient enrollments by 2025 [7][9] Group 2: Company Announcements - Microchip Biotech plans to repurchase shares amounting to no less than 10 million yuan and no more than 15 million yuan, with a repurchase price not exceeding 47.46 yuan per share, within a 12-month period [10] - The company has completed GMP compliance checks for the third production line of Sigleth sodium and is advancing GMP certification for the new formulation line, with plans to add a production capacity of 1.2 billion tablets by 2027 [6][9] - The top ten shareholders include Boao Biological Group, holding 30,627,198 shares, representing 7.51% of the total shares [8]